Global guidelines standardize phage therapy for resistant infections
Summary and headline written by AI from the source article. How we work
An international group of twenty organizations, led by the German Society for Infectious Diseases, created the first global guideline for personalized phage therapy.
These viruses specifically target and kill bacteria, offering a potential treatment when antibiotics fail. The guideline details recommendations for selecting and testing phages, manufacturing, quality control, and monitoring patient responses. Until now, no unified standards existed for using phages as medicine, creating challenges for safe and effective treatment.
The new guideline emphasizes evaluating each case individually with input from physicians, microbiologists, and phage experts to ensure the chosen phage effectively combats the specific bacterial strain causing the infection. Researchers acknowledge more controlled clinical trials are needed to definitively prove phage therapy’s effectiveness, but initial data suggest positive outcomes. In a Belgian case series, 77% of 100 patients with difficult-to-treat infections showed improved conditions after receiving phage therapy, and the targeted bacteria disappeared in 61% of those cases.
Frankfurt University Medical Center in Germany has already begun using the guideline in a program that successfully treated 10 patients since February 2026 with individualized phage treatments delivered through various methods like intravenous injection or nasal spray. The guideline will be reviewed annually for updates and is valid through June 29, 2030.
